Hansa Biopharma AB (publ) - Special Call Transcript
Ladies and gentlemen, welcome to the update on the regulatory path for imlifidase in the U.S. (Operator Instructions) I'll now hand the call over to CEO, Søren Tulstrup. Speakers, please begin.
¸ - ()-&
Thank you very much, operator. Good afternoon to those of you in Europe, and good morning to those in the U.S. Welcome to the Hansa Biopharma conference call regarding the update on the regulatory path in the U.S. for imlifidase in highly sensitized patients. I'm Søren Tulstrup, CEO of Hansa Biopharma. With me today, I have our Chief Scientific Officer, Christian Kjellman, and our CFO, Donato Spota. Out presentation should take about 10 minutes, and after that we'll take your questions.
Please turn to Slide 2. Please allow me to draw your attention to our forward-looking statement which applies to this presentation.
Now please turn to Slide 3. On today's call, we'll go through the agenda as follows. First, we'll provide a
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |